Role of a mutant p53 protein in apoptosis: Characterization of a function independent of transcriptional trans-activation

International Journal of Oncology

Volumn 13, Issue 1, 1998, Pages 107-114

  Guillouf, Christel ^a   Rosselli, Filippo ^b   Tjin Tham Sjin, Robert ^c   Moustacchi, Ethel ^b   Hoffman, Barbara ^a   Liebermann, Dan A ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DIF   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; DNA damaging agents; G2 checkpoint; p53

Indexed keywords

DNA FRAGMENT; PROTEIN P53; RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; GENETIC TRANSCRIPTION; IMMUNOBLOTTING; IRRADIATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TEMPERATURE; TUMOR SUPPRESSOR GENE;

EID: 0031804874     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.1.107     Document Type: Article

References (62)

1. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
2. Zhan Q, Carrier F and Fornace AJ Jr: Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 13:4242-4250, 1993.
3. Fritsche M, Haessler C and Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318, 1993.
4. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci. USA 89: 7491-7495, 1992.
5. Yonish-Rouach E, Resnitsky D, Lotem J, Sachs L, Kimchi A and Oren M: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991.
6. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature: 362: 849-852, 1993.
7. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
8. Lee JM and Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742-5746, 1993.
9. Lotem J and Sachs L: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82: 1092-1096, 1993.
10. Bargonetti J, Friedman PN, Kern SE, Volgestein B and Prives C: Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083-1091, 1991.
11. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C and Volgestein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711, 1991.
12. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Volgestein B: Definition of a consensus binding site for p53. Nat Genet 1:45-49, 1992.
13. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871, 1992.
14. Farmer GJ, Bargonetti J, Zhu H, Friedman P, Prywes R and Prives C: Wild-type p53 activates transcription in vitro. Nature 358: 83-86, 1992.
15. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Volgestein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-829, 1992.
16. Zambetti GP, Bargonetti J, Walker K, Prives C and Levine AJ: Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 6: 1143-1152, 1992.
17. Papathanasiou MA, Kerr NC, Robbins JH, McBride OW, Alamo IJ, Barret SF, Hickson ID and Fornace AJ Jr: Induction by ionizing radiation of the gadd45 gene in cultured human cells: lack of mediation by protein kinase C. Mol Cel Biol 11: 1009-1016, 1991.
18. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ Jr: A mammalian cell cycle checkpoint utilizing p53 and gadd45 is defective in Ataxia-telangiectasia. Cell 71: 587-597, 1992.
19. Gaelles C, Helmberg A and Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223, 1994.
20. Gottlieb E, Lindner S and Oren M: Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells. Cell Growth Differ 7: 301-310, 1996.
21. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka M, Bishoff FZ, Tainsky MA and Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233-1238, 1990.
22. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
23. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
24. Raycroft L, Wu H and Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249: 1049-1051, 1990.
25. Unger T, Nau MM, Segal S and Minna JD: p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11: 1383-1390, 1992.
26. Finlay CA, Hinds PW and Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
27. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C and Levine AJ: Gain of function mutations in p53. Nat Genet 4: 42-45, 1993.
28. Chin KV, Ueda K, Pastan I and Gottesaman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462, 1992.
29. Deb S, Jackson CT, Subler MA and Martin DW: Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 66: 6164-6170, 1992.
30. Selvakumaran M, Lin HK, Myashita T, Wang HG, Krajesky S, Reed JC, Hoffman B and Liebermann DA: Immediate early upregulation of bax expression by p53 but not TGFß1: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798, 1994.
31. Eliyahu D, Goldfinger N, Pinhasi-Kimchi O, Shaulsky G, Skurnik Y, Arai N, Rotter V and Oren M: Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3: 313-320, 1988.
32. Hinds P, Finlay C and Levine AJ: Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63: 739-746, 1989.
33. Guillouf C, Grana X, Selvakumaran M, De Luca A, Giordano A, Hoffman B and Liebermann DA: Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest. Blood 85: 2691-2698, 1995.
34. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B and Liebermann DA: p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 10: 2263-2270, 1995.
35. Tilly JL and Hsueh AJW: Microscale autoradiographic method for the qualitative and quantitative analysis of apoptotic DNA fragmentation. J Cell Physiol 154: 519-526, 1993.
36. Lord KA, Abdollahi A, Hoffman-Liebermann B and Liebermann DA: Dissection of the immediate early response of myeloid leukemia cells to terminal differentiation and growth inhibitory stimuli. Cell Growth Differ 1:637-645, 1990.
37. Selvakumaran M, Liebermann DA and Hoffman-Liebermann B: Deregulated c-myb disrupts IL-6/LIF induced myeloid differentiation prior to c-myc: Role in leukemogenesis. Mol Cell Biol 12: 2493-2500, 1992.
38. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K (eds.) Current Protocols in Molecular Biology. Greene and Wiley-Interscience, New York, 1992.
39. Selvakumaran M, Lin HK, Tjin Tham Sjin R, Reed JC, Liebermann DA and Hoffman B: The novel primary response gene Myd118 and the proto-oncogenes myb, myc, and bcl-2 modulate transforming growth factor ß1-induced apoptosis of myeloid leukemia cells. Mol Cell Biol 14: 2352-2360, 1994.
40. Lord KA, Abdollahi A, Hoffman-Liebermann B and Liebermann DA: Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentation. Mol Cell Biol 13: 841-851, 1993.
41. Gannon JV and Lane DP: Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature 349: 802-806, 1991.
42. Ginsberg DD, Michalovitz M, Ginsberg D and Oren M: Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol 11: 582-585, 1991.
43. Martinez J, Georgoff I, Martinez J and Levine AJ: Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5: 151-159, 1991.
44. El-Deiry WS, Tokino K, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: Topological control of p21WAFI/CIP1 expression in normal and neoplastic tissues. Cell 75: 817-825, 1993.
45. Juven T, Barak Y, Zaubcrman A, George DL and Oren M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416, 1993.
46. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
47. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
48. Haupt Y, Rowan S, Shaulian E, Vousden KH and Oren M: Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9: 2170-2183, 1996.
49. Yonish-Rouach E, Deguin V, Zaitchouk T, Breugnot C, Mishal Z, Jenkins JR and May E: Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 11: 2197-2205, 1995.
50. Ryan JJ, Danish R, Gottlieb CA and Clarke MF: Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13:711-719, 1993.
51. Michalovitz D, Helevy O and Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680, 1990.
52. Chen JY, Funk WD, Wright WE, Shay JW and Minna JD: Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8: 2159-2166, 1993.
53. Zhang W, Funk WD, Wright WE, Shay JW and Deisseroth AB: Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8: 2555-2559, 1993.
54. Harper JW, Adami GR, Keyomarsi NW and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
55. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinase. Nature 366: 701-704, 1993.
56. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
57. Attardi LD, Lowe SW, Brugarolas J and Jacks T: Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 15: 3693-3701, 1996.
58. Wagner AJ, Kokontis JM and Hay N: Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf/cip1. Genes Dev 8: 2817-2830, 1994.
59. Sabbatini P, Lin J, Levine AJ and White E: Essential role for p53-mediated transcription in EIA-induced apoptosis. Genes Dev 9: 2184-2192, 1995.
60. Lee S, Elenbaas B, Levine A and Griffith J: p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020, 1995.
61. Jayaraman J and Prives C: Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-1029, 1995.
62. Wang, XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Friedberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeimakers JHJ, Forrester H and Harris CC: p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 10: 188-195, 1995.